Aytu BioScience announces U.S. co-promotion agreement for Primsol

Tuesday March 29, 2016 0 comments Tags: Englewood, Aytu BioScience, Primsol, Josh Disbrow, Allegis Pharmaceuticals

 

ENGLEWOOD --   Aytu BioScience,  Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced the company has entered into a co-promotion agreement for Primsol® (trimethoprim hydrochloride) oral solution with Allegis Pharmaceuticals, a commercial-stage specialty pharmaceutical company focused on the U.S. pediatric market.Aytu_logoUSE

Under the agreement, Aytu said Allegis will exclusively promote Primsol to pediatricians across the U.S. Aytu will retain all other rights in the U.S. and around the world and continue to market the product in urologic indications.

Aytu said Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well-established in current guidelines for treating uncomplicated urinary tract infections (UTIs). 

The product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients who experience adverse reactions to sulfamethoxazole ("sulfa"). Aytu said Primsol is also indicated for the treatment of acute otitis media, or middle ear infection, caused by susceptible organisms in children age six months to 12 years. Otitis media is the leading pediatric infection in the U.S.

"We are excited to initiate this partnership with Allegis and believe that this co-promotional agreement makes sense on multiple levels,” said Josh Disbrow, Aytu’s CEO.

“Allegis has an experienced commercial team and a strong sales history in pediatrics -- where Primsol prescribing has been consistent since the product's launch -- with a product portfolio that is complementary to Primsol. Placing the pediatric-focused marketing efforts with Allegis enables Aytu to further monetize Primsol through a long-term promotional commitment, while enabling Aytu to stay focused on our core therapeutic area of urology. 

“We expect Allegis to regain some of the historical prescribing of pediatricians as we align our efforts to the urology market, a specialty that has historically prescribed over one-quarter of Primsol prescriptions in the U.S."